JF
NAMS icon

Jump Financial’s NewAmsterdam Pharma NAMS Stock Holding History

Jump Financial’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,401
Closed -$653K – 1871
2024
Q4 		$653K Buy
+25,401
New +$540K 0.01% 955

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Jump Financial's NAMS Position: Q1 2025 in Review

Jump Financial sold out of NewAmsterdam Pharma (NAMS) in Q1 2025, closing a stake of 25,401 shares — an estimated $653K sold.

Jump Financial first reported a position in NAMS in Q4 2024 and held it in 1 quarter. The position peaked at $653K in Q4 2024. 126 funds tracked by Wall St. Rank hold NAMS as of Q1 2025.

  • Jump Financial reported no remaining NewAmsterdam Pharma position as of Q1 2025 after selling out during the quarter.
  • Jump Financial sold 25,401 NewAmsterdam Pharma shares in Q1 2025, an estimated $653K.
  • Jump Financial first reported a position in NewAmsterdam Pharma in Q4 2024 and held it in 1 quarter.
  • Jump Financial's NewAmsterdam Pharma position peaked at $653K in Q4 2024.
  • 126 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2025.

Based on Jump Financial's 13F filing for Q1 2025, filed 14 May 2025.